ClinicalTrials.Veeva

Menu

The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus.

A

Ain Shams University

Status and phase

Not yet enrolling
Phase 2

Conditions

Chronic Kidney Disease
Uremic Pruritus

Treatments

Drug: Activated Charcoal
Drug: Probiotic Blend Capsule

Study type

Interventional

Funder types

Other

Identifiers

NCT06579066
Uremic Pruitus

Details and patient eligibility

About

This study aims to evaluate the efficacy and safety of probiotics versus activated charcoal in management of chronic kidney disease patients suffering from uremic pruritus.

Patient data collection

Demographic data:The following data will be collected from the patient records; including age, sex, weight, height.

History Taking :Including patient's medical history, past surgical history, family medical history, and medications the patient is taking or may have recently stopped taking.

A patient's medical history may also include information about allergies, etiology of uremic pruritus.

Laboratory examinations:The following laboratory data to be measured at baseline and after the duration of treatment (4 weeks)

  1. Serum levels of indoxyl sulfate (IS)
  2. Kidney Function tests: BUN, Creatinine
  3. Electrolytes test: sodium, potassium, chloride ,ionized calcium, phosphorus

Dermatological examination: Base on

  1. measure Visual Analoge Scale Score(VAS).
  2. measure Dermatology life quality index (DLQI).

Full description

Chronic kidney disease-associated pruritus (CKD-aP) , also called uremic pruritus (UP) is a critical problem defined as un pleasant sensation that desire to itch and scratch experienced by people with chronic kidney disease (CKD) patients . Pruritus is the most common skin symptoms related with uremia and has a major clinical effect being associated strongly with poor quality of life , impaired sleep and increased mortality, so it's important to explore an efficient treatment option for it. Although the pathogenesis of pruritus remains largely unclear, it is demonstrated that pruritus is mainly ascribed to the retention of uremic solutes.

Gut microbiome has gained attention and is increasingly noted to play a significant role in a number of disorders including CKD. Patients with CKD can be characterized with lower bacterial richness and diversity. Like the gut, human skin has its own microbiome. Recent study showed that CKD patients with pruritus had a different bacterial community comparing to those without pruritus indicating that altered skin microbiome associated with pruritus in patients with CKD and also with accumulation of uremic toxins in skin. So, the skin microbiome plays a potential role in regulating the skin symptoms in CKD patients. Therefore, these findings might be useful for making probiotics supplements to relieve patient's skin symptoms or renal damage.

Indoxyl sulfate (IS) is one of the most potent protein bound uremic toxins derived from the gut microbes. IS is generated by bacterial metabolism of trptophan to indole. The serum IS was significantly elevated in patients with CKD associated pruritus. Moreover, High serum IS concentration has a strong relationship with pruritus severity and a negative impact on quality of life. Therefore, IS may represent a potential therapeutic target to reduce the pruritus severity.

To decrease serum IS levels either decrease IS production by using probiotic supplementation or decrease IS intestinal absorption by addition of activated charcoal as an adsorbent agent has been evaluated in uremic patients.

Probiotics are defined as live microorganisms that consumed in adequate amounts; confer a health effect on the host. Probiotics supplement regulating the immune system and improving the skin barrier. Probiotics work by competing with pathogenic organisms for nutrients, which prevent the growth of harmful bacteria. So, probiotics has a key role in improving the microbiota.Several clinical trials are being carried out on the efficacy of probiotics for the treatment of many skin problems. Some trials also showed that probiotics has a role in reducing of protein bound uremic toxin such indoxyl sulfate (IS).We hope that this study forms a contribution to promoting probiotics as a novel therapeutic approach for the treatment of uremic pruritus.

Activated charcoal is a powerful, intestinal adsorbent within the gastrointestinal (GI) tract, effectively trapping various chemicals. These captured substances are then retained within the charcoal matrix, preventing or reducing their absorption into the blood stream. Activated charcoal has been found to effectively eliminate urea and other uremic toxin such as indoxyl sulfate due to its ability to bind with IS and expelling it through feces. It's also showed that the usage of activated charcoal resulted in decreasing pruritus severity and improving the quality of life of patients without serious side effects.

Enrollment

123 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult Patients with uremic pruritus aged from 18 years and older will be enrolled in the study.

Exclusion criteria

  1. Patients with psoriasis, atopic dermatitis or any other condition that can justify pruritus.
  2. Patient undergoing dialysis.
  3. Patients with known allergy to Activated charcoal or probiotics supplements.
  4. Patients who are non-compliant.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

123 participants in 3 patient groups

probiotics
Experimental group
Description:
Patients will administer Linex ® capsule orally along with the standard care of therapy for duration of 4 weeks. Dose: Capsule once daily
Treatment:
Drug: Probiotic Blend Capsule
activated charcoal
Experimental group
Description:
Patients will administer Charclone® 1000mg tab orally along with the standard care of therapy for duration of 4 weeks. Dose: Tablet three times daily.
Treatment:
Drug: Activated Charcoal
Control
No Intervention group
Description:
Patients will administer standard care of therapy alone Telfast®120mg tablet for duration of 4 weeks.. Dose: Tablet once daily

Trial contacts and locations

0

Loading...

Central trial contact

Aliaa Mohamed Ashraf

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems